Other formats:
BibTeX
LaTeX
RIS
@misc{2365870, author = {Žáčková, Daniela}, booktitle = {Brno-Vienna Collaboration meeting 2023, General Hospital of Vienna, Vienna, Rakousko, 2. 6. 2023}, keywords = {chronic myeloid leukemia; HALF; CLINICAL TRIAL; TKI}, language = {eng}, title = {CML stopping trial HALF: Concept and Initial Data}, url = {https://czecrin.cz/projekty/kh-half/}, year = {2023} }
TY - SLIDE ID - 2365870 AU - Žáčková, Daniela PY - 2023 TI - CML stopping trial HALF: Concept and Initial Data KW - chronic myeloid leukemia KW - HALF KW - CLINICAL TRIAL KW - TKI UR - https://czecrin.cz/projekty/kh-half/ N2 - A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system. ER -
ŽÁČKOVÁ, Daniela. CML stopping trial HALF: Concept and Initial Data. In \textit{Brno-Vienna Collaboration meeting 2023, General Hospital of Vienna, Vienna, Rakousko, 2. 6. 2023}. 2023.
|